



biogen idec

The content of this letter has been agreed with the European Authorities, following the EMEA's Press Release of 20 March 2008.

Dear Health Care Professional,

Summary

- Reports of serious liver injury in patients receiving TYSABRI ▼ have been received from the market.
- Signs of liver injury including elevated serum hepatic enzymes and total bilirubin occurred as early as six days after the first dose but have also been reported later during treatment.
- In a small number of cases, liver dysfunction that had resolved after cessation of therapy reoccurred upon resumption of dosing with TYSABRI.
- Patients treated with TYSABRI should be monitored as appropriate for signs of liver dysfunction and be instructed to contact their physician in case of signs and symptoms suggestive of liver injury.
- Treatment should be discontinued in cases of significant liver injury.

Further information on the safety concern

Serious hepatic events have been reported in which a contributory role for TYSABRI could not be excluded. None of the reported cases led to death or liver transplantation.

In the clinical trials of TYSABRI in MS and Crohn's disease, although serious hepatic events consistent with liver injury were reported, the proportions of affected individuals was comparable in patients receiving active drug or placebo. The post-marketing data has prompted the Marketing Authorisation Holder to amend the Summary of Product Characteristics. The incidence of these serious events is not precisely known as the reports arise from post-marketing surveillance, however they are likely to be rare, since they were not observed in the clinical studies involving over 3000 patients studied for up to 2 years or longer. Details of the changes to the Summary of Product Characteristics and patient leaflet are attached as Annex 1.

Further information on recommendations to healthcare professionals

- Patients treated with TYSABRI should be monitored as appropriate for signs of liver dysfunction and be instructed to contact their physician in case of signs and symptoms suggestive of liver injury.
- In cases of significant liver injury, treatment should be discontinued.
- The Marketing Authorisation Holder will be updating the educational information, which is supplied to healthcare professionals as part of the risk minimisation for TYSABRI.

Call for reporting

If you have observed similar cases, please report adverse reactions to the MHRA or to Biogen Idec Limited.

Suspected adverse reactions should be reported directly to the MHRA via the Yellow Card Scheme (information can be found at www.yellowcard.gov.uk) or to Biogen Idec Limited [0800 028 6639]

Communication information

For further information please contact: -

Medical Information on 0800 028 6639

Annexes:

Text of the revised Product Information (with changes made visible)

Yours faithfully,

Dr Elias Kouchakji
Elan



Dr Glyn Belcher
Biogen Idec

